

Cambridge University Press

978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance,
Biological Substrates and Treatment Opportunities

Edited by Roger S. McIntyre

Frontmatter

[More information](#)

Cognitive Impairment in Major Depressive Disorder

Clinical Relevance, Biological Substrates,
and Treatment Opportunities

Cambridge University Press
978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance,
Biological Substrates and Treatment Opportunities
Edited by Roger S. McIntyre
Frontmatter
[More information](#)

Cambridge University Press

978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance,
Biological Substrates and Treatment Opportunities

Edited by Roger S. McIntyre

Frontmatter

[More information](#)

Cognitive Impairment in Major Depressive Disorder

Clinical Relevance, Biological Substrates, and
Treatment Opportunities

Edited by

Roger S. McIntyre, MD, FRCPC

Roger S. McIntyre is Professor of Psychiatry and Pharmacology, University of Toronto, Executive Director of the Brain and Cognition Discovery Foundation (BCDF), and Head of the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada. Dr. McIntyre has been named by Thomson Reuters as one of the World's Most Influential Scientific Minds.

Associate Editor

Danielle S. Cha, HBS, MSc Candidate

Researcher at the Institute of Medical Science, University of Toronto, and the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada



CAMBRIDGE
UNIVERSITY PRESS

Cambridge University Press

978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance, Biological Substrates and Treatment Opportunities

Edited by Roger S. McIntyre

Frontmatter

[More information](#)

CAMBRIDGE
UNIVERSITY PRESS

University Printing House, Cambridge CB2 8BS, United Kingdom

Cambridge University Press is part of the University of Cambridge.

It furthers the University's mission by disseminating knowledge in the pursuit of education, learning, and research at the highest international levels of excellence.

www.cambridge.org

Information on this title: www.cambridge.org/9781107074583

Cognitive Impairment in Major Depressive Disorder, ed. Roger S. McIntyre. Published by Cambridge University Press.

© Cambridge University Press 2016

This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2016

Printed in United Kingdom by Clays, St Ives plc

A catalogue record for this publication is available from the British Library

Library of Congress Cataloguing-in-Publication data

Cognitive impairment in major depressive disorder : clinical relevance, biological substrates, and treatment opportunities / edited by Roger S. McIntyre ; associate editor, Danielle S. Cha.
p.; cm.

Includes bibliographical references and index.

Summary: "Major depressive disorder (MDD) is a leading cause of disability globally in both developed and developing nations. The staggering economic costs attributable to MDD are largely a consequence of impairment in role function. Evidence indicates that disturbance in the domain of cognitive function in individuals with MDD is the principal determinant of health outcome. This is the first book to comprehensively explore the domain of cognition in MDD. The literature describing cognitive dysfunction is reviewed with particular focus on clinical determinants, pathophysiology, and causative factors. The patient subpopulations most susceptible are defined. A summary of contemporary assessment tools for research and clinical purposes is provided. Multimodality treatments and prevention strategies are described. This book is an invaluable resource for psychiatrists, neuropsychologists and other members of the mental health team, as well as for policy makers, vocation rehabilitation experts, disability providers, and other stakeholders interested in improving health outcomes in MDD"—Provided by publisher.

ISBN 978-1-107-07458-3 (hardback)

I. McIntyre, Roger S., editor. II. Cha, Danielle S., editor.

[DNLM: 1. Cognition Disorders—etiology. 2. Depressive Disorder, Major—complications. 3. Cognition Disorders—physiopathology. 4. Cognition Disorders—therapy. WM 204]

RC537

616.85'270651—dc23

2015016410

ISBN 978-1-107-07458-3 Hardback

Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or third-party internet websites referred to in this publication, and does not guarantee that any content on such websites is, or will remain, accurate or appropriate.

Every effort has been made in preparing this book to provide accurate and up-to-date information which is in accord with accepted standards and practice at the time of publication. Although case histories are drawn from actual cases, every effort has been made to disguise the identities of the individuals involved. Nevertheless, the authors, editors, and publishers can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors, and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.

Contents

List of figures vii
List of tables ix
List of contributors xi
Preface xv
List of abbreviations xvii

Part I – Clinical relevance of cognitive dysfunction in major depressive disorder

1	Does cognitive dysfunction predate the onset of incident depression? 1
	Julia Buthmann, Danielle S. Cha, and Roger S. McIntyre
2	Understanding the importance of cognitive dysfunction and cognitive change in major depressive disorder 15
	Paul Maruff and Judith Jaeger
3	Cognition in MDD: implications for primary care 30
	Larry Culpepper
4	Neurocognition in pediatric depression 47
	Dwight F. Newton, Melanie R. Naiberg, and Benjamin I. Goldstein
5	Neuroanatomy of cognition in major depressive disorder 60
	Guy M. Goodwin
6	Hot and cold cognition in major depressive disorder 69
	Oliver J. Robinson, Jonathan P. Roiser, and Barbara J. Sahakian

7	Social cognition and emotional processing in major depressive disorder 81
	Philippe Fossati and Sophie Hinfray
8	The role of social cognition in major depressive disorder 92
	Bernhard T. Baune and Michael Weightman
9	Are cognitive deficits in major depressive disorder progressive? 110
	Marie Laure Cléry-Melin and Philip Gorwood
10	Implications of cognitive impairments on functional outcomes in major depressive disorder 125
	Tracy L. Greer and Cassandra R. Hatt

Part II – Underlying biological substrates associated with cognitive dysfunction in major depressive disorder

11	Cognition and biomarkers in major depressive disorder: endophenotype or epiphenomenon? 145
	Shane J. McInerney, Philip Gorwood, and Sidney H. Kennedy

vi	Contents
12	Inflammation and cognition in major depressive disorder 160 Bernhard T. Baune
13	HPA axis and cognitive dysfunction in mood disorders 179 Rebecca Strawbridge and Allan H. Young
14	White matter neurobiology and cognitive dysfunction in major depressive disorder 194 Geoffrey Chern-Yee Tan and Kang Sim
15	Insulin resistance and implications for hippocampal volume/function and the default mode network 209 Heather A. Kenna, Tonita E. Woolie, Danielle R. Balzafore, and Natalie L. Rasgon
	Part III – Evaluating cognitive dysfunction in major depressive disorder
16	Measuring the mind: detecting cognitive deficits and measuring cognitive change in patients with depression 229 John E. Harrison
17	Subjective measures of cognitive dysfunction in major depressive disorder 242 Raymond W. Lam
	Part IV – Treatment opportunities for ameliorating cognitive dysfunction in major depressive disorder
18	Neuroscience of functional outcomes and treatment targets in major depressive disorder 257 Lisanne M. Jenkins, Amy Peters, Rachel H. Jacobs, and Scott A. Langenecker
19	Treatment of cognitive dysfunction in adults with major depressive disorder 274 Roger S. McIntyre, Kahlood Syeda, and Danielle S. Cha
20	A novel treatment targeting cognitive dysfunction in mood disorders 289 Kamilla W. Miskowiak
21	Cognitive remediation for major depressive disorder 306 Christopher R. Bowie
22	Exercise and cognition 321 Guy Faulkner, Markus J. Duncan, and Mehala Subramaniapillai
	<hr/>
	<i>Index</i> 339
	<i>Color plate section between pp. 233 and 234</i>

Cambridge University Press

978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance,
Biological Substrates and Treatment Opportunities

Edited by Roger S. McIntyre

Frontmatter

[More information](#)

Figures

- 1.1 The impact of hot and cold cognitive processes on depressive symptoms. 7
- 2.1 Comparison of the magnitude of impairment in psychomotor function, attention, working memory, and learning in patient groups with Alzheimer's disease, chronic schizophrenia, and major depressive disorder. 17
- 2.2 Proportion of the sample in three studies, Alzheimer's disease, chronic schizophrenia, and major depressive disorder, who reported that they were in full- or part-time employment or education. 18
- 2.3 Comparison of the magnitude of impairment in psychomotor function, attention, working memory, and learning in patient groups with major depressive disorder and in healthy adults who had low-level alcohol intoxication (blood alcohol concentration = 0.05%) or who had been awake for 24 hours. 19
- 2.4 Magnitude of impairment in psychomotor function, attention, working memory, and learning in an employed group of people with major depressive disorder. 22
- 6.1 The impact of depression on cold cognitive function. Reproduced with permission from Rock et al. (2014). 71
- 6.2 A neurocognitive model of depression. Reproduced with permission from Roiser et al. (2012). 73
- 7.1 SENSO framework showing biological, cognitive, neural, and behavioral responses following social rejection or threat of rejection. 87
- 11.1 Neuropsychological model of depression. Adapted from Roiser et al. (2013), with permission. 150
- 12.1 A phase-specific neuroimmune model of clinical depression with remission. 163
- 12.2 A phase-specific neuroimmune model of clinical depression: chronic major depressive episode with progressive depressive features and cognitive dysfunction. 164
- 12.3 Immune dysfunction impacts on emotion deregulation and cognitive dysfunction in MDD. 170
- 13.1 A simplified diagram depicting the HPA axis and its feedback mechanism. 180
- 15.1 Scatterplot between HOMA-IR and right hippocampal volume corrected for total brain volume. 217
- 15.2 Scatterplot between HOMA-IR and MMSE (Rasgon et al., 2011). 218

viii	List of figures
15.3	Functional connectivity maps for the higher insulin and lower insulin contrast groups. (A) Brain regions that showed positive association with seed regions' time series. (B) Between-group differences in functional connectivity. 219
15.4	Functional connectivity maps for the higher insulin and lower insulin groups. Brain regions that displayed positive associations with seed regions' time series. 220
16.1	Cognitive tests and their associated domains identified by Lee et al. (2012). 234
16.2	Possible grouping of endpoints employed in the FOCUS study by cognitive domain. 238
17.1	Percentage of subjects with clinically significant cognitive complaints based on the BC-CCI. Adapted from Iverson & Lam (2013). 243
17.2	Functional impairment (as measured by SDS and WPAI scores) increases with greater self-perceived cognitive dysfunction (as measured by PDQ-D-5 Severity Category). Adapted from Saragoussi et al. (2013). 243
17.3	Percentage of subjects in each severity category on the BC-CCI. Adapted from Iverson & Lam (2013). 247
17.4	Mean change from baseline to week 8 in PDQ total score and PDQ subscale scores. Adapted from McIntyre et al. (2014). 249
19.1	Standardized effect size (Cohen's d) of Vortioxetine (10 mg and 20 mg) on objective neuropsychological measures (McIntyre et al., 2014). 278
20.1	(a): The percentage improvement from individual baseline in a memory composite score. (b): The percentage improvement from individual baseline in the cognition composite score of overall speed of complex cognitive processing score. 301
20.2	Schematic overview of the three lines of research that together point to erythropoietin (EPO) as a novel candidate compound to target persistent cognitive dysfunction in mood disorder. 302
21.1	Number of minutes of online homework on a computerized cognitive training program, as a function of treatment response status (defined as magnitude of change in cognitive ability). 313
21.2	A simplistic model of how using cognitive training exercises might lead to changes in brain function, ultimately manifesting in adaptive everyday behavior changes. 314
21.3	A model of cognitive remediation as a psychotherapy that represents the three main pillars of therapist-guided intervention. 314
21.4	An illustration of how tangible, action-based activities can be used to foster transfer of cognitive skills from computer-based training to everyday functional tasks. 315
21.5	The model of psychotherapy known as Action-Based Cognitive Remediation. 317

Tables

A1.1	Summary of research findings supporting cognitive deficits acting as an antecedent to the development of depression.	8
2.1	Impairment in work performance in patients with MDD with cognitive dysfunction who were employed or in school at the time of assessment.	21
3.1	Questions on commonly used depression assessment tools that might indicate hot and cold cognitive problems in patients with depression.	33
3.2	Tests for objective assessment of cognitive functions.	36
3.3	Potential impact of hot and cold cognitive deficits on patients' roles as patient.	42
4.1	Summary of studies regarding cognition among adolescents with major depressive disorder.	49
8.1	Case-control studies investigating differences in social cognitive performance between patients with major depressive disorder and controls.	96
8.2	Case-control studies investigating social cognitive performance in remitted major depressive disorder.	101
8.3	Association between severity of depressive symptoms and social cognitive performance.	103
9.1	Overview of longitudinal studies on the burden of MDD on cognitive functions.	114
10.1	Overview of studies measuring both functional and cognitive outcomes in major depressive disorder.	129
11.1	Cognitive deficits in different phases of MDD.	147
13.1	Main findings comparing cognition, mood disorder, and HPA-axis measurement.	186
17.1	Subjective cognitive scales that are psychometrically validated in major depressive disorder.	246
19.1	Method factors to determine direct effect of cognition in adults with MDD.	282
19.2	Treatments with demonstrated direct effect on disparate measures of cognitive function in individuals with MDD.	284
19.3	Treatments with possible, yet unproven, direct effects on disparate measures of cognitive function in younger individuals with MDD.	286

Cambridge University Press
978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance,
Biological Substrates and Treatment Opportunities
Edited by Roger S. McIntyre
Frontmatter
[More information](#)

x	List of tables
20.1	Animal studies of the effects of systemically administered erythropoietin on depression-relevant cognitive function. 292
20.2	Randomized controlled proof-of-concept studies of the effects of single erythropoietin administration on hippocampus-dependent memory, executive function, and emotional processing in healthy individuals. 295
20.3	Randomized controlled proof-of-concept studies of the effects of single erythropoietin administration on hippocampus-related memory and emotional processing in depressed patients. 298
20.4	Randomized controlled trials of long-term erythropoietin treatment in patients with different neuropsychiatric disorders. 300

Cambridge University Press

978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance,
Biological Substrates and Treatment Opportunities

Edited by Roger S. McIntyre

Frontmatter

[More information](#)

Contributors

Danielle R. Balzafore

Adjunct Professor, Palo Alto University,
Palo Alto, CA, USA

Bernhard T. Baune

Professor and Chair of Psychiatry,
University of Adelaide, Adelaide, Australia

Christopher R. Bowie

Department of Psychology, Department of
Psychiatry, and Centre for Neuroscience
Studies, Queen's University, Kingston,
Ontario, Canada and Centre for Addiction
and Mental Health, Toronto,
ON, Canada

Julia Buthmann

Mood Disorders Psychopharmacology
Unit, University Health Network,
Toronto, ON, Canada

Danielle S. Cha

Mood Disorders Psychopharmacology
Unit, University Health Network, Institute
of Medical Science, University of Toronto,
Toronto, Canada

Marie Laure Cléry-Melin

Centre Hospitalier Sainte-Anne (CMME),
Paris Descartes University, Paris, France

Larry Culpepper

Professor of Family Medicine, Boston
University School of Medicine, and
Attending Physician, Boston Medical
Center, Boston MA, USA

Markus J. Duncan

Faculty of Kinesiology and Physical
Education, University of Toronto, Toronto,
ON, Canada

Guy Faulkner

School of Kinesiology, University of British
Columbia, Vancouver, BC, Canada

Philippe Fossati

Professor of Psychiatry, Institut du Cerveau
et de la Moelle (ICM), Social and Affective
Neuroscience Laboratory, Pitié-Salpêtrière
Hospital, Department of Psychiatry, APHP,
Université Paris 6, Paris, France

Benjamin I. Goldstein

Associate Professor of Psychiatry and
Pharmacology, University of Toronto,
Toronto, ON, Canada

Director, Centre for Youth Bipolar
Disorder, Sunnybrook Health Sciences
Centre, Toronto, ON, Canada

Guy M. Goodwin

Department of Psychiatry, Warneford
Hospital, University of Oxford, Oxford, UK

Philip Gorwood

Centre of Psychiatry and Neuroscience
(Paris Descartes University), Centre
Hospitalier Sainte-Anne (CMME), Paris,
France

Tracy L. Greer

Associate Professor of Psychiatry,
University of Texas Southwestern Medical
Center, Dallas, TX, USA

John E. Harrison

Principal Consultant, Metis Cognition Ltd.,
Warminster, UK

Associate Professor, Alzheimer Center,
VU Medical Center, Amsterdam, the
Netherlands

Cambridge University Press
978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance,
Biological Substrates and Treatment Opportunities
Edited by Roger S. McIntyre
Frontmatter
[More information](#)

xii	List of contributors
-----	----------------------

Cassandra R. Hatt
University of Texas Southwestern Medical
Center, Dallas, TX, USA

Sophie Hinfray
Institut du Cerveau et de la Moelle, Social
and Affective Neuroscience Laboratory,
Pitié-Salpêtrière Hospital, Department
of Psychiatry, Paris, France

Rachel H. Jacobs
Research Assistant Professor, Department
of Psychiatry, University of Illinois at
Chicago, Chicago, IL, USA

Judith Jaeger
Clinical Professor of Psychiatry and
Behavioral Sciences, Albert Einstein College
of Medicine, Bronx, New York, USA

Lisanne M. Jenkins
Postdoctoral Research Associate,
Department of Psychiatry, University
of Illinois at Chicago, Chicago,
IL, USA

Heather A. Kenna
Department of Psychiatry and Behavioral
Sciences, Stanford, CA, USA

Sidney H. Kennedy
Department of Psychiatry, University
of Toronto, University Health Network,
Toronto, ON, Canada
Arthur Sommer-Rotenberg Chair in
Suicide Studies, St Michael's Hospital,
Toronto, ON, Canada

Raymond W. Lam
Professor and Associate Head for Research,
Department of Psychiatry, University of
British Columbia, Vancouver, BC, Canada;
Medical Director, Mood Disorders Centre,
Djavad Mowafaghian Centre for Brain
Health, Vancouver, BC, Canada

Scott A. Langenecker
Associate Professor of Psychiatry and
Psychology, University of Illinois
at Chicago, Chicago, IL, USA

Paul Maruff
Florey Institute for Neuroscience and
Mental Health, University of Melbourne,
Parkville, Australia

Shane J. McInerney
University Health Network, University of
Toronto, Toronto, ON, Canada

Roger S. McIntyre
Professor of Psychiatry and Pharmacology,
the University of Toronto;
Executive Director of the Brain and
Cognition Discovery Foundation,
Head of the Mood Disorders
Psychopharmacology Unit, University
Health Network, Toronto, ON, Canada

Kamilla W. Miskowiak
Psychiatric Centre Copenhagen,
Copenhagen University Hospital,
Rigshospitalet, Copenhagen, Denmark

Melanie R. Naiberg
Sunnybrook Health Sciences Centre,
Toronto, ON, Canada

Dwight F. Newton
Sunnybrook Health Sciences Centre,
University of Toronto, Toronto, ON, Canada

Amy Peters
Department of Psychiatry, College of
Medicine, University of Illinois at Chicago,
Chicago, IL, USA

Natalie L. Rasgon
Professor of Psychiatry and Behavioral
Sciences, Stanford University Medical
Center, Stanford, CA, USA

Oliver J. Robinson
Institute of Cognitive Neuroscience,
University College London, London, UK

Jonathan P. Roiser
Institute of Cognitive Neuroscience,
University College London, London, UK

Barbara J. Sahakian
Department of Psychiatry, MRC/
Wellcome Trust Behavioural and Clinical
Neuroscience Institute, University of
Cambridge, Cambridge, UK

Cambridge University Press
978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance,
Biological Substrates and Treatment Opportunities
Edited by Roger S. McIntyre
Frontmatter
[More information](#)

Kang Sim
Department of General Psychiatry,
Research Division, Institute of Mental
Health, Singapore
Yong Loo Lin School of Medicine, National
University of Singapore, Singapore

Rebecca Strawbridge
Centre of Affective Disorders, Department
of Psychological Medicine, Institute of
Psychiatry, King’s College London,
London, UK

Mehala Subramaniapillai
Faculty of Kinesiology and Physical
Education, University of Toronto,
Toronto, ON, Canada

Kahlood Syeda
Mood Disorders Psychopharmacology
Unit, University Health Network,
Toronto, ON, Canada

Geoffrey Chern-Yee Tan
Institute of Mental Health, National
Healthcare Group, Agency for Science,
Technology and Research, Singapore
Michael Weightman
Discipline of Psychiatry, School of
Medicine, University of Adelaide, Adelaide,
Australia
Tonita E. Wroolie
Clinical Assistant Professor, Psychiatry and
Behavioral Sciences, Stanford School of
Medicine, Stanford, CA, USA

Allan H. Young
Centre of Affective Disorders, Department
of Psychological Medicine, Institute of
Psychiatry, King’s College London,
London, UK

Cambridge University Press
978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance,
Biological Substrates and Treatment Opportunities
Edited by Roger S. McIntyre
Frontmatter
[More information](#)

Cambridge University Press

978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance,
Biological Substrates and Treatment Opportunities

Edited by Roger S. McIntyre

Frontmatter

[More information](#)

Preface

The global economic topography has witnessed a tectonic plate shift toward the “human capital economy.” The skillsets required to be an effective participant in the global workforce were previously described as “simple” and “manual,” but today are characterized as “complex” and “cognitive.” An observation, aligned with the conceptual macroeconomic framework of the Solow–Swan effect, was that the troika of technological advance, productivity, and workplace opportunity are positively correlated. The digital revolution, however, represents an exception to the foregoing correlation insofar as the unprecedented technological capability for automation, lean manufacturing, and efficiency has increased productivity (in some sectors), yet has decreased workplace opportunities.

Economists often refer to the “polarization” of the workforce, referring to the significant reduction of “midlevel” positions and instead a disproportion of job availability for those at the entry level, often low skill and low paying positions, or high skillset positions requiring significant education attainment. The emphasis on the STEMs (Science, Technology, Engineering, and Math) as an asset to increase the probability of entering into higher paying jobs instantiates the relevance of cognitive capability in the global economy. “Cost of illness” and “workplace depression” studies consistently identify depressive disorders as a leading cause of cost and disability globally. Symptom structure analyses indicate that residual cognitive problems are identified by patients as a principal quality of life detractor and barrier to full functional recovery.

It has been recognized for a long time that cognitive dysfunction is an intrinsic aspect of depressive disorders. Notwithstanding, cognitive function in depressive disorders has received relatively less attention than other common and/or severe brain disorders across the developmental trajectory (e.g. bipolar disorder, schizophrenia, autism, dementing disorders). A highly reproducible finding has been that a substantial proportion of adults with depressive disorders have clinically significant deficits across disparate cognitive functions during and between acute episodes. The pertinence of cognitive dysfunction in depression is underscored by the observation that cognitive dysfunction is a critical mediator of adverse psychosocial outcomes as well as work-related disability. For the past several decades, remission of symptoms has been emphasized as the desired therapeutic objective in depressive disorders. Notwithstanding, most individuals with depressive disorders in remission continue to evince prominent psychosocial difficulties. The disconnection between conventional mood symptoms and functional outcome provided the impetus for identifying proximate mediators of functional outcome. Depressive disorders, like most brain disorders, are impairing largely due to the pervasiveness and persistence of cognitive deficits.

The moniker, “Systemically Important Financial Institutions” (SIFIs), a key output of the Dodd-Frank Act (2010), refers to financial organizations that are so critical to the global economic infrastructure that their demise would have catastrophic economic effects globally. Cognition in depressive disorders can also be conceptualized as a SIFI: a “Systemically Important Functional Index.” In other words, cognitive function amongst individuals with depressive disorders is “Too Big to Fail” given its centrality to human positive mental health, day-to-day function, and the human capital economy.

Cambridge University Press
978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance,
Biological Substrates and Treatment Opportunities
Edited by Roger S. McIntyre
Frontmatter
[More information](#)

xvi	Preface
-----	---------

This textbook contains contributions from global experts in psychiatry, psychology, primary care, psychometrics, neuroscience, and healthcare policy. The overarching aims of this textbook are: to increase awareness of cognitive dysfunction in major depression; to underscore its impact from clinical and population health perspectives; to review the underlying pathoetiological substrates as well as moderational influences; and to provide practical approaches to assessment, measurement, treatment, and prevention. Across many chronic diseases (e.g. heart disease, diabetes mellitus), optimal health outcomes are achieved by identifying proximate determinants of health outcomes. The evidence indicates that in depressive disorders (as well as most other brain disorders), cognitive function is the critical determinant of health outcome.

It is my hope that this book serves not only as an encyclopedic repository of information but also provides a comprehensive survey of the “cognitive landscape” capturing both the surreal advances that have been made in the field as well as directions for future research. I thank all of the contributors for their enormous effort and commitment to this field. In addition, I want to particularly thank the patients and families I’ve had the privilege to meet throughout my career who have inspired me and have always reminded me that Osler was correct when he stated, “Listen to your patient, he is telling you the diagnosis.”

Dr. Roger S. McIntyre

Cambridge University Press

978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance,
Biological Substrates and Treatment Opportunities

Edited by Roger S. McIntyre

Frontmatter

[More information](#)

Abbreviations

3HK: 3-hydroxykynurenine

A β : amyloid-beta

AACAP: American Academy of Child and Adolescent Psychiatry

ABCR: action-based cognitive remediation

ABM: attention bias modification

ACC: anterior cingulate cortex

ACGC: Applied Cognition-General Concerns

ACT: alpha(1)-antichymotrypsin

ACTH: adrenocorticotrophic hormone

AD: Alzheimer's disease

ADAS-cog: Alzheimer's Disease Assessment Scale – Cognitive Subscale

ADHD: attention-deficit/hyperactivity disorder

ADL: activities of daily living

AFT: Advanced Finances Task

AIC: anti-inflammatory cytokines

AmNART: American National Adult Reading Test

ANT: Attention Network Task

APA: American Psychiatric Association

AQP4: aquaporin-4

ASRS: Attention Deficit/Hyperactivity Disorder Self-Report Scale

AVLT: Auditory Verbal Learning Test

AVP: vasopressin

BAC: blood alcohol concentration

BASIS: Behavior and Symptom Identification Scale

BBB: blood-brain barrier

BC-CCI: British Columbia Cognitive Complaints Inventory

BD: bipolar disorder

BDI-II: Beck Depression Inventory, 2nd Edition

BDNF: brain-derived neurotrophic factor

BDQ: Brief Disability Questionnaire

BLA: basolateral nucleus

BMI: body mass index

BOLD: blood oxygen level detection

BPI: Brief Pain Index

xviii	List of abbreviations
-------	-----------------------

- BRIEF-A: Behavior Rating Inventory of Executive Function
BSAT: Brixton Spatial Anticipation Test
CA: cornu ammonis
CADASIL: cerebral autosomal dominant arteriopathy, subcortical infarcts, and leukoencephalopathy
CADSS: Clinician-Administered Dissociative States Scale
CAM: complementary alternative medicine
CAMCOG: Cambridge Cognitive Examination
CAMCOR: Cambridge Cognitive Examination-Revised
cAMP: cyclic adenosine monophosphate
CANTAB: Cambridge Neuropsychological Test Automated Battery
CAT: computerized adaptive testing
CBB: CogState Brief Battery
CBT: cognitive behavioral therapy
CCN: cognitive control network
CDQ: Cognitive Dysfunction Questionnaire
CDR: Cognitive Drug Research
CeA: central nucleus
CEPO: carbamylated erythropoietin
CFS: chronic fatigue syndrome
CGI-I: Clinical Global Impression – Improvement
CGI-S: Clinical Global Impression – Severity
CGS-I/S: Clinical Global Scale – Improvement/Severity
CI: confidence interval
CIAS: Cognitive Impairment Associated with Schizophrenia
CNS: central nervous system
COWAT: Controlled Oral Word Association Test
CPFQ: Cognitive and Physical Functioning Questionnaire
CPT: Continuous Performance Test
CR: cognitive remediation
CREB: cAMP response element-binding protein
CRF: adrenocorticotrophic-releasing factor
CRH: corticotropin-releasing hormone
CRP: C-reactive protein
CRT: Choice Reaction Time
CRT: cognitive remediation therapy
CSF: cerebrospinal fluid
CSH: cognitive speed hypothesis
CT: computerized tomography

- CVLT: California Verbal Learning Test
dACC: dorsal anterior cingulate cortex
DBS: deep brain stimulation
DDS: Denver Developmental Screening Test
DEFS: Deficits in Executive Function Scale
DHEA: dehydroepiandrosterone
DLPFC: dorsolateral prefrontal cortex
DLRF: daily living and role functioning
DM2: type II diabetes
DMN: default mode network
dmPFC: dorsomedial prefrontal cortex
DSM: *Diagnostic and Statistical Manual of Mental Disorders*
DSST: Digit Symbol Substitution Test
DST: dexamethasone suppression test
DTI: Diffusion-tensor imaging
DZ: dizygotic
EAAT: excitatory amino acid transporter
ECT: electroconvulsive therapy
EF: executive function
EN: emotion network
EPO: erythropoietin
EPO-R: erythropoietin receptor
ERP: event-related potentials
EWPS: Endicott Work Productivity Scale
FA: fractional anisotropy
FDA: Food and Drug Administration
fMRI: functional magnetic resonance imaging
FPRS: Faces Pain-Rating Scale
GABA: gamma-aminobutyric acid
GFAP: glial fibrillary acidic protein
Glut 1: glucose transporter 1
GM: Gray Matter
GR: glucocorticoid receptor
GSK3 β : glycogen synthase kinase 3 beta
HAM-D: Hamilton Psychiatric Rating Scale for Depression
HC: healthy control
HC: hippocampal
HIF: hypoxia inducible factor
HOMA-IR: Homeostatic Model Assessment – Insulin Resistance

xx	List of abbreviations
----	-----------------------

- HPA: hypothalamic–pituitary–adrenal
HR: hazard ratio
IAPS: International Affective Picture System
IBS: irritable bowel syndrome
IC: insular cortex
ICD: International Classification of Diseases
IFN γ : interferon-Gamma
IGF-1: insulin-like growth factor 1
IGT: Iowa Gambling Task
IL: interleukin
ILF: inferior longitudinal fasciculus
IMDCP: International Mood Disorders Collaborative Project
IPT: interpersonal psychotherapy
IQ: intelligence quotient
IR: insulin resistance
IS: imperative signal
ISH: *in situ* hybridization
IU: international unit
JAK: janus kinase
JNK: C-jun N-terminal kinases
LIFE-RIFT: Longitudinal Interval Follow-Up Evaluation–Range of Impaired Functioning Tool
LTD: long-term depression
LTP: long-term potentiation
MADRS: Montgomery–Åsberg Depression Rating Scale
MAO-A: monoamine oxidase A
MAPK: mitogen-activated protein kinase
MCCB: MATRICS Consensus Cognitive Battery
MCI: mild cognitive impairment
MD: mean difference
MDD: major depressive disorder
MDE: major depressive episode
MDPU: Mood Disorders Psychopharmacology Unit
MMSE: Mini Mental Status Exam
MNS: mirror neural system
MoCA: Montreal Cognitive Assessment
MOS-Cog: Medical Outcomes Study Cognitive Functioning Scale
MPFC: medial prefrontal cortex
MR: mineralocorticoid receptor

- MRI: magnetic resonance imaging
MS: multiple sclerosis
MSIF: Multidimensional Scale of Independent Functioning
MZ: monozygotic
NAA: *N*-acetylaspartate
NAcc: nucleus accumbens
NART: National Adult Reading Test
NCS-R: National Comorbidity Survey Replication
NEAR: Neuropsychological and Educational Approach to Remediation
NF- κ B: nuclear factor kappa-light-chain-enhancer of activated B cells
NIMH: National Institute of Mental Health
NMDA: *N*-methyl-D-aspartate
NTB: Neuropsychological Test Battery
OCD: obsessive-compulsive disorder
ODD: oppositional defiant disorder
OFC: orbitofrontal cortex
OR: odds ratio
PA: physical activity
PCC: posterior cingulate cortex
PDQ: Perceived Deficits Questionnaire
PET: positron emission tomography
PFC: prefrontal cortex
PHQ: Patient Health Questionnaire
PI3K: phosphoinositide 3-kinase
PICs: pro-inflammatory cytokines
PKB: protein kinase B
PRMQ: Prospective and Retrospective Memory Questionnaire
PROMIS: Patient Reported Outcome Measurement Information System
PST: prednisolone suppression test
QA: quinolinic acid
QIDS-SR: Quick Inventory of Depressive Symptomatology-Self Report
Q-LES-Q: Quality of Life Enjoyment and Satisfaction Questionnaire
rACC: rostral anterior cingulate cortex
RAVLT: Rey Auditory Verbal Learning Test
RBANS: Repeatable Battery for the Assessment of Neuropsychological Status
RCI: Reliable Change Index
RCT: randomized controlled trial
RDoC: Research Domain Criteria
RNA: ribonucleic acid

xxii	List of abbreviations
------	-----------------------

- ROS: reactive oxygen species
RR: relative risk
rs-fMRI: resting state functional magnetic resonance imaging
RSO: relation to self and others
rTMS: repetitive transcranial magnetic stimulation
SAME: S-adenosyl methionine
SCG: subgenual cingulate cortex
SCL-90: Symptom Checklist-90
SD: standard deviation
SDS: Sheehan Disability Scale
SE: standard error
SF-12: 12-item Short Form Health Survey
SGAC: subgenual anterior cingulate cortex
SLF: superior longitudinal fasciculus
SMD: standardized mean difference
SMILE: Standard Medical Interventions and Longterm Exercise
SN: salience network
SNPs: single-nucleotide polymorphisms
SNRI: serotonin-norepinephrine reuptake inhibitor
SPC: superior parietal cortex
SRE: self-reference effect
SRT: Simple Reaction Time
SSPA: Social Skills Performance Assessment
SSPG: steady state plasma glucose
SSRI: selective serotonin reuptake inhibitor
STAR*D: Sequenced Treatment Alternatives to Relieve Depression
STAT: signal transducer and activation of transcription
TAK-1: transforming growth factor β -activated kinase 1
TBRI: to be remembered item
tDCS: transcranial direct current stimulation
TGF- β : transforming growth factor beta
TMT: Trail Making Test
TNF: tumor necrosis factor
TNFR: tumor necrosis factor receptor
ToM: theory of mind
TRD: treatment-resistant depression
TrkB: tyrosine kinase receptor B
TSR: threat of social rejection
UPSA: University of California San Diego Performance-Based Skills Assessment

Cambridge University Press
978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance,
Biological Substrates and Treatment Opportunities
Edited by Roger S. McIntyre
Frontmatter
[More information](#)

- VBM: voxel-based morphometry
- VEGF: vascular endothelial growth factor
- VFT: Verbal Fluency Test
- VLPFC: ventrolateral prefrontal cortex
- WAIS: Wechsler Adult Intelligence Scale
- WCST: Wisconsin Card Sorting Test
- WHO: World Health Organization
- WHS: World Health Survey
- WISC-III: Wechsler Intelligence Scale for Children-Third Edition
- WLQ: Work Limitations Questionnaire
- WM: white matter
- WM: working memory
- WMD: weighted mean difference
- WMH: white matter hyperintensities
- WMS: Wechsler Memory Scale
- WPAI: Work Productivity and Activity Impairment
- YoE: years of education